Before taking Camzyos(mavacamten)

CAMZYOS requires careful monitoring due to the risk of heart failure and significant drug interactions.

Key Precautions and Risk Management for CAMZYOS Therapy

CAMZYOS can cause systolic dysfunction and heart failure, necessitating regular LVEF monitoring via echocardiogram before and during treatment. The drug is contraindicated with strong CYP2C19 inhibitors, moderate to strong CYP2C19 or CYP3A4 inducers, and certain negative inotropes due to increased risk of adverse cardiac events. CAMZYOS is only available through the REMS program, requiring prescriber, patient, and pharmacy certification. Females of reproductive potential must use effective contraception during treatment and for 4 months after the last dose. Use in pregnancy, lactation, and pediatric populations is not specified in the description.